

Original Article

Screening for latent tuberculosis infection in patients who are candidate for biological therapies in Spain? A multidisciplinary survey[☆]

Sarai Quirós,^{a,*} David de la Rosa,^b Ane Uranga,^c Rosario Madero,^d Rosanel Amaro,^e Nuria Bruguera,^f Julia A. García,^g C. Gómez,^h David Iturbe,ⁱ Rubén Lera,^j Lydia Luque,^k Abel J. Martínez,^l Patricia Mínguez,^m Annie Navarro,ⁿ Gema Sánchez,^o Guillermo Suárez-Cuadrón^p

^a Servicio de Neumología, Hospital General Universitario La Paz-Carlos III- Cantoblanco, Madrid, Spain

^b Servicio de Neumología, Hospital Plató, Barcelona, Spain

^c Servicio de Neumología, Hospital de Galdakao-Usansolo, Bizkaia, Spain

^d Sección de Bioestadística-IdiPAZ, Hospital General Universitario La Paz, Madrid, Spain

^e Servicio de Neumología, Hospital Clinic, Barcelona, Spain

^f Servicio de Neumología, Hospital Comarcal Sant Jaume de Calella, Barcelona, Spain

^g Servicio de Neumología, HUA Txagorritxu, Álava, Spain

^h Servicio de Neumología, Hospital General de la Defensa, Zaragoza, Spain

ⁱ Servicio de Neumología, Hospital Universitario Marqués de Valdecilla, Santander, Spain

^j Servicio de Neumología, Hospital Doctor Peset, Valencia, Spain

^k Servicio de Neumología, Hospital Moisès Broggi, Barcelona, Spain

^l Servicio de Neumología, Hospital Universitario de Albacete, Albacete, Spain

^m Servicio de Neumología, Hospital Puerta de Hierro, Madrid, Spain

ⁿ Servicio de Neumología, Mutua de Terrassa, Barcelona, Spain

^o Servicio de Neumología, HGU Gregorio Marañón, Madrid, Spain

^p Servicio de Neumología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

ARTICLE INFO

Article history:

Received 9 February 2018

Accepted 12 April 2018

Available online 14 August 2018

Keywords:

Biological therapies

Latent tuberculosis infection

Tuberculosis

Tumor necrosis factor-alpha

ABSTRACT

Introduction: Treatment with biological therapies increases the incidence of tuberculous disease. The introduction of systematic screening for latent tuberculosis infection in patients who are to receive these therapies has reduced this risk. In 2016, the consensus document on the prevention and treatment of tuberculosis in patients who are candidates for biological treatment was published in Spain. The main objective of this study was to evaluate adherence to these guidelines.

Methods: Multicenter, descriptive, observational study via an anonymous online survey sent to medical societies involved in biologics.

Results: We received 747 responses. Most respondents performed screening at the right time in the right patients (93.7%). Only 36.6% of respondents requested the appropriate diagnostic test, while 56.3% correctly recommended chemoprophylaxis. Up to 96% were familiar with the recommended chemoprophylaxis regimens, while only 63.9% initiated them at the right time. The specialist area that participated most and screened most patients for latent tuberculosis infection was rheumatology (54%). In most cases, pulmonologists were involved in an advisory capacity.

Conclusions: This study shows poor overall adherence to recommendations, with only 56% of respondents reporting appropriate compliance. The incidence of tuberculous disease in patients who are to receive biological therapies could be reduced further by emphasizing the importance of the right diagnostic test and use of the diagnostic algorithm for latent tuberculosis infection.

© 2018 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

[☆] Please cite this article as: Quirós S, de la Rosa D, Uranga A, Madero R, Amaro R, Bruguera N, et al. ¿Cómo realizamos el cribado de infección tuberculosa latente en pacientes candidatos a terapias biológicas en España? Una encuesta multidisciplinar. Arch Bronconeumol. 2018;54:510–517.

* Corresponding author.

E-mail address: saraiquiros@icloud.com (S. Quirós).

¿Cómo realizamos el cribado de infección tuberculosa latente en pacientes candidatos a terapias biológicas en España? Una encuesta multidisciplinar

R E S U M E N

Palabras clave:

Terapias biológicas
Infección tuberculosa latente
Enfermedad tuberculosa
Factor de necrosis tumoral alfa

Introducción: El tratamiento con terapias biológicas aumenta la incidencia de enfermedad tuberculosa. La implementación sistemática del cribado de la infección tuberculosa latente en pacientes que van a recibir estas terapias ha conseguido reducir el riesgo de desarrollarla. En 2016 se publicó en España el Documento de consenso sobre la prevención y el tratamiento de la tuberculosis en pacientes candidatos a tratamiento biológico. El objetivo principal del estudio fue evaluar la adherencia al mismo.

Métodos: Estudio multicéntrico, descriptivo, observacional en forma de encuesta anónima online, difundida entre las diferentes sociedades médicas que trabajan con biológicos.

Resultados: Se recibieron 747 respuestas. La mayoría de los encuestados realizaba el cribado en el momento adecuado y con la indicación correcta (93,7%). Solo un 36,6% de los encuestados solicitaba las pruebas diagnósticas adecuadas, mientras que el 56,3% acertaron las indicaciones de quimioprofilaxis. Hasta el 96% conocía las pautas de quimioprofilaxis recomendadas, mientras que solo el 63,9% las iniciaba en el momento adecuado. La especialidad con más participación y que más realizaba el cribado de infección tuberculosa latente fue reumatología (54%). En la mayoría de los casos, los neumólogos participaban como consultores.

Conclusiones: Este estudio pone de manifiesto un bajo grado de adherencia a las recomendaciones, realizando un cumplimiento aceptable el 56% de los encuestados. Enfatizando en las pruebas diagnósticas adecuadas y en el algoritmo diagnóstico de infección tuberculosa latente, se podría reducir aún más la incidencia de enfermedad tuberculosa en los pacientes que van a recibir terapias biológicas.

© 2018 SEPAR. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

The emergence of tuberculosis (TB) among patients who start biologics for the treatment of immune-mediated inflammatory diseases has alerted the medical community to the risk of reactivated TB infection associated with these therapies.^{1,2} The relative risk of TB in patients receiving these treatments has increased between 1.6- and 25-fold in recent decades,^{2–7} and the agents specifically associated with an increased risk are the anti-tumor necrosis factor- α s infliximab and adalimumab. Two North American studies observed increased incidences of TB in patients with rheumatoid arthritis treated with infliximab (52.2–54 cases per 100 000 patients per year) compared to those who did not receive biologics (6.2 cases per 100 000 patients per year).^{4,8–10} The French RATIO registry recorded an incidence of TB among patients receiving infliximab of 116.7 cases per 100 000 patients/year, 12.2-fold higher than in the general population.¹¹ In Spain, Carmona et al. described a fourfold increase in the risk of TB among rheumatoid arthritis patients receiving biologics, compared with the general population.¹² In Spain, more than 10% of candidates for biologics have latent TB infection (LTI), illustrating the scale of the population at risk of reactivated TB.¹³

In view of this evidence, international medical societies included LTI screening in their protocols as a requirement before starting biologics.¹⁴ This intervention has led to a 78–90% decrease in TB, although no studies have formally evaluated adherence to these recommendations. The Consensus Document on the Prevention and Treatment of Tuberculosis in Patients who are Candidates for Biological Treatment was published in Spain in 2016.^{15–17}

The Emergent Group of the Tuberculosis and Respiratory Infections Study Area of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) conducted this study in collaboration with various medical societies, in order to evaluate the degree of adherence to the recommendations of the national consensus document.

Materials and methods

Study design

This was a multicenter, descriptive, observational study based on an anonymous online SurveyMonkey[®] questionnaire. Six scientific societies (Dermatology, Rheumatology, Digestive Diseases, Internal Medicine, Infectious Diseases, and Pulmonology) were invited to participate. The medical societies were contacted directly by email via their web site, and each invited their respective members to participate, using the online survey link.

Study objectives

The primary objective was to determine adherence to the consensus recommendations. Secondary objectives were to identify which specialists performed LTI screening, to determine if screening was carried out in the respondent's center and to identify heterogeneity in LTI management, recommendations with a lower degree of uptake, the most widely used chemoprophylaxis, and the role of the respiratory medicine department in the process.

Data collection

The survey consisted of 10 questions with 5 possible answers, some of which included an open-ended response (Table 1). It was not a prerequisite to be responsible for decision-making in this type of patient in order to participate in the survey. Indeed, since the responsibility and engagement of specialists varies among centers, we were interested to determine whether the professionals who might be involved at any stage of the process (whether prescribing biologics, seeing patients receiving these treatments, or managing tuberculosis) would know what to do. Respondents were not obliged to answer all the questions, and in some cases two answers were possible. Questions 1–4 collected general data, and questions

Table 1
Screening for latent tuberculosis infection in patients who are candidates for biological therapies in Spain: survey questions.

Question 1 What is your specialty?

1. Respiratory medicine
2. Internal medicine/infectious diseases
3. Rheumatology
4. Dermatology
5. Gastrointestinal

Question 2 Do you screen candidates for biological therapies for latent tuberculosis infection in your hospital?

1. Yes
2. No
3. Don't know

Question 3 Which hospital departments carry out latent tuberculosis infection screening in candidates for biological therapies?

1. Respiratory medicine
2. Rheumatology
3. Dermatology
4. Internal medicine/infectious diseases
5. Gastrointestinal

Question 4 What is the role of the respiratory medicine departments in latent tuberculosis infection screening in candidates for biological therapies?

1. None
2. They supervise the process
3. They give advice if doubts arise
4. They are responsible for the whole process
5. The patient is referred to Respiratory medicine only if screening is positive

Question 5 Which candidates for biological therapies undergo latent tuberculosis infection screening?

1. Latent tuberculosis infection screening is not initially performed
2. Screening is performed in patients with a history of previous exposure to tuberculosis
3. Screening is only performed when the patient develops symptoms suggestive of TB after starting biological therapy
4. Latent tuberculosis infection screening is performed in all patients who are candidates for biological therapies, always before starting treatment
5. **Latent tuberculosis infection screening is performed in all patients who are candidates for biological therapies, but not always before starting treatment**

Question 6 What tests do you request for latent tuberculosis infection screening?

1. Chest X-ray + TT
2. Chest X-ray + IGRA
3. **Chest X-ray + TT + IGRA**
4. Chest X-ray + either TT or IGRA
5. **Chest X-ray + TT. If TT is negative, I request IGRA**

Question 7 If the TT is negative, what do you do next?

1. I don't need to do anything else, treatment with biologics can begin.
2. Repeat the TT in 2 weeks due to the booster effect
3. **Request IGRA before starting treatment with biologics**
4. I would start treatment with biologics, but I would monitor the patient with annual TTs during this treatment
5. I would request IGRA before starting treatment with biologics only if the patient is immunosuppressed or has recently received corticosteroids

Question 8 If the TT is positive, what do you do next?

1. Repeat it in 2 weeks, in case it was a false-positive
2. Request IGRA to confirm the result
3. I would administer chemoprophylaxis for at least 2 weeks before starting treatment with biologics, after ruling out active TB
4. I would start chemoprophylaxis and biologics, after ruling out active TB.
5. **I would administer chemoprophylaxis for at least 4 weeks before starting treatment with biologics, after ruling out active TB**

Question 9 Is there any situation in which you would start chemoprophylaxis in a candidate for biologics with a negative TT and IGRA?

1. No, it is not indicated
2. Yes, in immunosuppressed patients or those who have recently received corticosteroids
3. Yes, if there is evidence of untreated TB on the chest X-ray
4. Yes, if there is epidemiological evidence of recent exposure to TB
5. **Yes, if either of the two previous options are applicable**

Question 10 If chemoprophylaxis is prescribed, what regimen do you use most often? Note treatment duration in comments

1. **Isoniazid alone**
2. Isoniazid with rifapentine
3. Rifampicin alone
4. **Isoniazid with rifampin**
5. I do not prescribe chemoprophylaxis; in this case, I refer the patient.

The correct answers are indicated in bold.

5–10 referred to the LTI screening consensus recommendations and chemoprophylaxis.

Acceptable adherence to the recommendations was taken as correct responses to four or more of questions 5–10 (at least 60% correct answers). In contrast, low adherence was taken as incorrect

responses to three or more of these questions (less than 50% correct). Scores were established according to the recently published "Health-Care Quality Standards in Chronic Obstructive Pulmonary Disease",¹⁸ which propose a methodology for quantifying the implementation of recommendations.




Figure 1. Medical specialty of respondents (percentage of total responses).

Statistical analysis

We used the SAS statistical program 9.3 (SAS Institute, Cary, NC, USA). Qualitative data were described as absolute frequencies and percentages, and quantitative data were reported by mean, median, and standard deviation (minimum, maximum). The number of questions 5–10 with correct responses was calculated. Comparisons between two groups were performed using the Mann–Whitney *U*-test, and between more than two groups using the Kruskal–Wallis test. Other qualitative variables were compared using the χ^2 -test or the Fisher’s exact test. All statistical tests were two-tailed, and values with $p < 0.05$ were considered significant.

Results

Questions 1–4

A total of 747 respondents completed the survey. Of these, 62% of the respondents were women and their mean age was 46 (± 10.6) years (25–81 years). In 98.1% of cases, LTI screening was performed in the respondent’s hospital. Participation by specialties is shown in Fig. 1. Highest participation was among rheumatology specialists (54%), and this group performed the most screening. Fig. 2 shows which specialists performed screening in each center.

The role of the pulmonologist in LTI screening is advisory in 43% of cases, in 38% they do not participate, in 8% they conduct the full study, in 3% of cases they supervise the process, and in 18% of cases they only see referrals with positive screening.

Questions 5–10

With regard to which biological therapy candidates should undergo LTI screening and when, 93.7% of respondents replied that they all should (correct answer). Another 2.8% perform screening, but not always before starting treatment; 1.6% do not screen any patients; 0.4% screen patients only if they develop clinical

symptoms suggestive of TB after starting biologics; 1.2% only screen patients with a history of contact with TB patients.

With regard to which tests should be requested for LTI screening, 36.6% of respondents selected simultaneous performance of chest X-ray, interferon gamma release assay (IGRA), and tuberculin test (TT) (correct answer). A total of 45.6% stated that they only performed chest X-ray and TT, and 11.4% performed chest X-ray and IGRA. The remaining 9% performed chest X-ray, and either TT or IGRA, but not both, even if they were negative.

With regard to the action to be taken in the case of negative TT, only 26.1% of respondents stated that they requested IGRA before starting biologics (correct answer); 57.6% would repeat TT after 2 weeks due to the booster effect; 9.4% would only request IGRA in immunosuppressed patients or those who had received corticosteroids. A total of 6.9% would not perform more tests and would initiate biologics at that time, although almost half of them (3.7%) would subsequently monitor their patients with annual TT during the biologics treatment period.

In response to the question on what to do in the case of positive TT, 63.9% of respondents replied that they would prescribe 4 weeks of chemoprophylaxis before starting biologics (correct answer); 15.4% would administer chemoprophylaxis for only 2 weeks before starting biologics; 8.7% would begin chemoprophylaxis and biologics simultaneously, after ruling out active TB; 0.8% would repeat TT in 2 weeks, in the case of a false-positive; and 11.2% would request IGRA to confirm the result.

In response to the question on whether in some cases they would start chemoprophylaxis if TT and IGRA were negative, 56.3% of the respondents replied that they would prescribe chemoprophylaxis if there was evidence of untreated TB on the chest X-ray or epidemiological evidence of recent exposure to TB (correct answer). In total, 19.1% would start chemoprophylaxis only if there was evidence of untreated TB on the chest X-ray; 13.6% would do so if there was evidence of recent exposure to TB; 3.6% would administer chemoprophylaxis to immunosuppressed patients or those who had recently received corticosteroids. In contrast, 17.4% would not start chemoprophylaxis in any of these cases, believing that it was not indicated.

Finally, when asked about chemoprophylaxis regimens, 96% replied correctly; most respondents would prescribe either isoniazid (H) in monotherapy (83%) or combined H and rifampicin (R) in special cases. The treatment duration proposed by most respondents (9 and 3 months, respectively) complied with the national consensus. Of the remaining respondents, 1.5% used monotherapy with R, 1.9% used H with pyrazinamide, and the same percentage used H with rifapentine.

Adherence study

The answers of 56% of respondents revealed adherence of at least 60% to the recommendations of the national consensus (correct responses to at least four of the six questions), although only




Figure 2. Professionals responsible for LTI screening by percentages (percentage of the total number of centers). Specialists from several areas may have responded from the same hospital, so the sum of percentages is greater than 100%.




Figure 3. Adherence to recommendations (four or more correct answers to questions 5–10), depending on whether the respondent's hospital performs LTI screening.

5.6% answered all six questions correctly. In contrast, 43% of respondents had a low percentage of correct answers (correct responses to three or fewer of the six questions). The performance of LTI screening in the respondent's own hospital was the only factor that showed a statistically significant association with greater adherence ($p=0.002$, Fig. 3). There were no significant differences in the degree of adherence according to medical specialty ($p=0.132$, Fig. 4). The rate of adherence by specialty is shown in Fig. 4.

Questions addressing in whom and when to perform LTI screening, and chemoprophylaxis regimens and duration, were answered correctly by 93 and 94% of respondents, respectively. In contrast, questions concerning the action to be taken in the case of negative TT and the tests that should be requested for screening were only answered correctly by 25 and 36% of respondents, respectively.

Discussion

This survey of a wide range of medical specialists involved in the administration of biologics revealed a low degree of adherence to the recommendations of the Spanish Consensus Document on the Prevention and Treatment of Tuberculosis in Patients who are Candidates for Biological Treatment.¹⁶ Only 56% of respondents

showed acceptable adherence to the recommendations. In 98% of cases, LTI screening was performed in the respondent's own hospital, and this was the only variable associated with better adherence to the consensus. The percentage of respondents who conduct the screening themselves and their role in the process is unknown. It can therefore be assumed that specialists who replied voluntarily to the survey participate directly or indirectly in LTI screening, or at least are aware of it as part of their training or clinical practice as a specialist involved either in the treatment of TB or the administration of biologics. Most respondents performed screening at the right time in the right patients. However, only 36% requested the right diagnostic tests and did not include the determination of IGRA in their routine practice. The questions that were most often answered correctly focus on when to begin chemoprophylaxis and which regimens to use. Nevertheless, it was striking to observe that almost 24% of respondents would not start chemoprophylaxis with a positive TT, and almost 20% would not prescribe it in any case with negative TT or IGRA, despite recent exposure to TB and/or immunosuppression.

These data are similar to those of the Spanish registry of systemic treatments in psoriasis (BIOBADADERM), recently published by Sánchez Moya et al.,¹⁷ which included more than 1400 patients with moderate–severe psoriasis, with an estimated LTI prevalence




Figure 4. Adherence to recommendations (four or more correct answers to questions 5–10), by medical specialty.

of 20.5%. Screening was conducted in 83% of patients, but only 51% adhered to the recommendations of the consensus document. No other studies have published on adherence to LTI recommendations.

Although all experts agree that the incidence of TB is greater at the beginning of biological therapy, discrepancies emerge regarding the minimum duration of chemoprophylaxis before the administration of biologics can safely begin. The initial guidelines recommended at least 1 month, but this interval was reduced to 3 weeks after publication of the study by Carmona et al.¹¹ Several recent studies, including the American recommendations of the Centers of Disease Control and Prevention, even suggest that both treatments can safely be started simultaneously without waiting.^{19,20} However, in Spain, the consensus document still recommends waiting 3 weeks, during which time proper chemoprophylaxis adherence and tolerance can be confirmed.¹⁵ According to the results of our study, most respondents (63.9%) follow this recommendation.

Evidence clearly supports the effectiveness of the recommendations after implementation in clinical practice.^{15,20,21} In Spain, data published by the Spanish registry of adverse events associated with biologics in rheumatic diseases (BIOBADASER) show a reduction of 74% in TB cases since 2002, the year in which LTI screening was introduced. However, estimates suggest that recommendations were not followed appropriately in up to 20% of cases, mainly due to the failure to repeat TT for the booster effect, leading to a sevenfold increase in the risk of TB.^{15,17,22} In the BIOBADASER registry, the incidence of TB was 20 times higher than that of the general

population before LTI screening became generalized and fell by 78% after its introduction. Thus, the rate of TB among rheumatoid arthritis patients receiving biologics has fallen by 86%, achieving similar rates as among patients not receiving these agents.¹⁵

A closer look at the tests requested for LTI screening shows that the consensus document recommends that patients are actively screened for a personal history of TB, contact with patients with active TB, and old TB lesions on chest X-ray and that IGRA and TT are performed simultaneously. The high rate of false-positives in TT, due mainly to previous vaccination, but also to its low sensitivity in patients receiving immunosuppressive therapy (up to 40% of false-negatives in some series),^{21,23–27} support the recommendation to routinely perform both TT and IGRA in these patients. However, our survey results also reveal that IGRA testing is not fully integrated into routine clinical practice. Repeating TT to increase sensitivity due to the booster effect is another of the most frequent errors in the survey responses: this practice is not recommended in the consensus document, as it reduces the specificity of the test and increases the rate of false positives.²⁸ The lack of adherence to the consensus recommendations regarding diagnostic tests revealed by the survey may be due to heterogeneity of the criteria specified by the different international medical societies.

According to the results of the survey, pulmonologists in most cases have an advisory role (43% of responses) or are involved in the management of TB. The respiratory medicine department is involved in screening in the centers of only 38% of the respondents. It could be assumed from these data that as pulmonologists do not routinely prescribe biologics, they see only a small num-

ber of candidates for biological therapies and that the specialists who do prescribe these drugs also perform LTI screening in their patients. Therefore, fewer than half of screening candidates will be seen in the respiratory medicine department. This may have been one of the reasons why 20% of the respondents reported that they would not start chemoprophylaxis in cases in whom it should be indicated, as these are specialists who have less experience in the management of TB.

The study has some limitations, mainly due to the anonymous online survey format, an approach which has methodological implications when it comes to drawing conclusions. The facilities available in each participating center (access to determination of IGRA, presence of pulmonologists, etc.) were not investigated, and this may have influenced some results. Nor do we know the total number of specialists contacted and, consequently, the overall proportion who responded. Furthermore, the overrepresentation of rheumatologists (54% of respondents) compared to the scant representation of specialties such as respiratory medicine, internal medicine, or infectious diseases may have biased the results of LTI management, since these are the three specialist departments that routinely see most patients of this type. Additionally, in this study, 98% of respondents stated that they perform LTI screening in their own hospitals, underlining the low degree of overall compliance.

Our study also has a number of strengths, including the fact that we collected the opinions of a broad sample of physicians who reported on their routine clinical practice, suggesting that the results are representative. Moreover, the questions were designed to allow a certain degree of variability, avoiding categorical responses or responses with only one possible answer, which also reflects real-world care in our setting.

Conclusions

It is now 15 years since the introduction of biologics and 1 year since the publication of the national consensus document on LTI screening in candidates for biological therapy, yet 43% of respondents still do not follow the recommendations with an acceptable degree of adherence.

Most respondents, irrespective of their specialty, identify the right candidates and the right time for LTI screening before starting biologics and select the correct regimen and duration of chemoprophylaxis. However, only 36% requested the appropriate diagnostic tests and most failed to act appropriately when TT was negative, one of the responses with the lowest percentage of correct answers. This suggests that IGRA testing is underused in daily clinical practice, perhaps because access is limited in some centers or because physicians are unaware of it. The fact that some medical societies make recommendations that diverge from the national consensus may also influence matters. It seems likely that if the implementation of the recommended diagnostic algorithm is reinforced, the incidence of TB, that has fallen since systematic LTI was introduced, may be reduced even further.

Conflicts of interest

The authors state that they have no conflict of interests.

Acknowledgements

- Statistics Department of HGU La Paz de Madrid.
- Spanish Societies of Rheumatology (SER), Spanish Academy of Dermatology and Venereology (AEDV), Digestive Diseases (EDPS), Internal Medicine (SEMI), Infectious Diseases and Clinical Microbiology (SEIMC), and Pulmonology and Thoracic Surgery (SEPAR).
- SEPAR Tuberculosis Working Group.

- SEIMC Mycobacterial Infections Study Group.
- Coordinator of the SEPAR Area of Tuberculosis and Respiratory Infections (TIR).
- Coordinator of the SEPAR Tuberculosis Integrated Research Program.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.arbr.2018.04.008.

References

1. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwietzman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor- α neutralizing agent. *N Engl J Med*. 2001;345:1098–104.
2. Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. *Clin Infect Dis*. 2004;39:295–9.
3. Hernández González F, Sanz Herrero F, Lloret Pérez T. New challenges for the pulmonologist in the diagnosis of latent tuberculosis infection: biological treatment and pulmonary tuberculosis. *Arch Bronconeumol*. 2011;47:375.
4. Nacci F, Matucci-Cerinic M. Tuberculosis and other infections in the anti-tumour necrosis factor- α (anti-TNF- α) era. *Best Pract Res Clin Rheumatol*. 2011;25:375–88.
5. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. *N Engl J Med*. 2000;343:1594–602.
6. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. *Arthritis Rheum*. 2004;50:1051–65.
7. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. *Arthritis Rheum*. 2004;50:3432–43.
8. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. *Arthritis Rheum*. 2004;50:372–9.
9. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. *Clin Infect Dis*. 2004;38:1261–5.
10. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. *Arthritis Rheum*. 2007;56:1125–33.
11. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. *Arthritis Rheum*. 2002;46:2287–93.
12. Carmona L, Hernández-García C, Vadillo C, Pato E, Balsa A, González-Alvaro I, et al. EMECAR Study Group. Increased risk of tuberculosis in patients with rheumatoid arthritis. *J Rheumatol*. 2003;30:1436–9.
13. Zabana Y, Domènech E, San Román AL, Beltrán B, Cabriada JL, Saro C, et al. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. *Inflamm Bowel Dis*. 2008;14:1387–91.
14. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. *Lancet Infect Dis*. 2003;3:148–55.
15. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al., BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. *Arthritis Rheum*. 2005;52:1766–72.
16. Mir Viladrich I, Dauden Tello E, Solano-Lopez G, Lopez Longo FJ, Taxonera Samso C, Sanchez Martinez P, et al. Documento de consenso sobre la prevención y el tratamiento de la tuberculosis en pacientes candidatos a tratamiento biológico. *Arch Bronconeumol*. 2016;52:36–45.
17. Sánchez-Moya AI, García-Doval I, Carretero G, Sánchez-Carazo J, Ferrandiz C, Herrera Ceballos E, et al. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain BIOBADADERM registry. *J Eur Acad Dermatol Venereol*. 2013;27:1366–74.
18. Soler Cataluña JJ, Calle M, Cosío BG, Marín JM, Monsó E, Alfageme I. Estándares de calidad asistencial en la EPOC. *Arch Bronconeumol*. 2009;45:196–203.
19. Winthrop KL, Novosad SA, Baddley JW, Calabrese L, Chiller T, Polgreen P, et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. *Ann Rheum Dis*. 2015;74:2107–16.
20. Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF. Tuberculosis associated with therapy against tumor necrosis factor alpha. *Arthritis Rheum*. 2005;52:2968–74.

21. Hsia EC, Schluger N, Cush JJ, Chaisson RE, Matteson EL, Xu S, et al. Interferon- γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. *Arthritis Rheum.* 2012;64:2068–77.
22. Gómez Reino JJ, Carmona L, Angel Descalzo M, Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. *Arthritis Rheum.* 2007;57:756–61.
23. García Gasalla M, Fernández Baca V, Mas AJ, Payeras Cifre A, Cifuentes-Luna C, Taberner-Ferrer R, et al. Use of Quantiferon-TB-Gold in Tube[®] test for detecting latent tuberculosis in patients considered as candidates for anti-TNF therapy in routine clinical practice. *Enferm Infect Microbiol Clin.* 2013;31:76–81.
24. Ponce de Leon D, Acevedo Vasquez E, Sanchez Torres A, Cucho M, Alfaro J, Perich R. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. *Ann Rheum Dis.* 2005;64:1360–1.
25. Ponce de Leon D, Acevedo Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. *J Rheumatol.* 2008;35:776–81.
26. Kleinert S, Tony HP, Krueger K, Detert J, Mielke F, Rockwitz K, et al. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon- γ release assays under real-life conditions. *Ann Rheum Dis.* 2012;71:1791–5.
27. Mariette X, Baron G, Tubach F, Lioté F, Combe B, Miceli-Richard C, et al. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. *Ann Rheum Dis.* 2012;71:1783–90.
28. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. *Clin Infect Dis.* 1993;17:968–75.